Generative AI in 2025 and Beyond: The Trends, Breakthroughs, and Forces Reshaping Our World KASATA – TechVoyager 12 min read · Just now Just now — Listen Share We are living through one of the most consequential technological transformations in human history. Generative AI — the branch of artificial intelligence capable of producing text, images, audio, video, code, and even scientific hypotheses — has moved from research labs into the fabric of everyday life with breathtaking speed. And yet, despite the headlines, the hype, and the hand-wringing, many people still struggle to grasp what is truly happening, why it matters, and where it is all heading. This article is a deep dive — a comprehensive look at the current state of generative AI, the major trends shaping its trajectory, the industries it is disrupting, and the profound questions it raises about creativity, labor, governance, and what it means to be human. Whether you are a developer, a business leader, an artist, or simply a curious observer, this piece is designed to give you a clear-eyed, well-structured understanding of where we are and where we are going. The Generative AI Landscape: A Brief Snapshot As of early 2025, generative AI has become a multi-hundred-billion-dollar industry with no signs of slowing down. The players are numerous and competitive: OpenAI’s GPT series, Google’s Gemini, Anthropic’s Claude, Meta’s Llama, Mistral, Cohere, xAI’s Grok, and dozens of open-source projects are all pushing the frontier simultaneously. What makes this moment distinct is the convergence of three enabling forces: massive compute infrastructure (GPUs, TPUs, custom AI chips), enormous training datasets, and architectural innovations — most notably the transformer architecture introduced in 2017. These three pillars have allowed AI systems to scale in a way that consistently unlocks emergent capabilities that surprise even their creators. But here is what most observers miss: we are not just dealing with better autocomplete. We are witnessing the emergence of systems that reason, plan, code, design, compose, and increasingly act in the world autonomously. The implications of that are staggering. Trend #1: The Rise of Multimodal AI One of the most significant shifts in the past two years has been the move from single-modality models to truly multimodal systems. Early language models could only process and generate text. Today’s frontier models — GPT-4o, Gemini 1.5 Pro, Claude 3.5 — can simultaneously understand and generate text, images, audio, and even video. This is not just a feature addition; it represents a fundamentally different way of interacting with AI. Consider what this enables in practice. A doctor can now photograph a skin lesion and ask an AI to describe what it sees, compare it to similar cases, and generate a differential diagnosis — all in a single conversation. An architect can sketch a rough layout by hand, photograph it, and have an AI refine it into a detailed floor plan with suggested material specifications. A journalist can upload hours of interview footage and have an AI generate a structured transcript, identify key themes, and suggest angles for the story. The frontier of multimodal AI is now expanding into real-time video understanding, native audio generation, and spatial reasoning. Google’s Gemini models have demonstrated the ability to analyze live video streams and answer questions about what is happening in real time. OpenAI’s voice mode has enabled conversations with AI that feel remarkably natural, complete with emotional inflection and back-and-forth dialogue. These capabilities are collapsing the distance between human and machine communication. Trend #2: Agentic AI — From Chatbots to Autonomous Actors If multimodality is the most visible trend, agentic AI is arguably the most transformative. For
Category: Uncategorized
-
Rajisha Vijayan unveils an UNTOLD story behind ‘Bison’ casting; says, ‘she was not the first choice for the Raji role’
Sometimes, the roles that come unexpectedly leave the biggest impact. Rajisha Vijayan is currently receiving strong praise for her performance in the latest Malayalam release ‘ Masthishka Maranam ,’ with many calling it one of the finest acts of her career. The Malayalam- Tamil film actress recently shared an interesting insight regarding her Tamil film ‘ Bison .’ She revealed that she was not the first choice for her character in the movie.Rajisha Vijayan reveals an untold storyIn an interview with OTT Play, Rajisha shared that director Mari Selvaraj approached several actresses before her for the sister’s role in Bison. The film stars Dhruv Vikram in the lead as Kittan, while Rajisha plays his sister Raaji. She explained that many actresses were hesitant to take up a sister character. When the offer finally reached her, she immediately said yes, as she was keen to collaborate with Mari Selvaraj once again.Mari Selvaraj-Rajisha Vijayan collaborationRajisha described working again with Mari Selvaraj as a proud moment. She said that when a director chooses to repeat an actor, it feels like a huge compliment and a sign of trust. Having earlier worked with him in Karnan, she felt happy that he believed she was suitable for the role. She also admitted that the character was emotionally demanding and required great effort. Though the journey was challenging, she feels satisfied with the response the film has received.’Bison’ – A powerful story with strong castThe story of ‘Bison’ tells of the life of a young Kabaddi player who encounters caste discrimination during his expedition. The film is receiving a lot of positivity for its plot and the performances of its crew members. In addition, the movie ‘Bison’ features other actors, such as Lal and Anupama Parameswaran. By now, it is obvious that Rajisha’s decision to embark on a project with roles many others rejected marked a significant turning point in her life, as it demonstrated that confidence and courage are the keys to success.
-
CapitaLand Ascott Trust Stapled Security (ATTRF) Presents at Citi’s Miami Global Property CEO Conference 2026 – Slideshow (OTCMKTS:ATTRF) 2026-03-03
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
-
How to separate properly tested high quality Kratom gummies from products that rely on bold claims and vague promises…
You’re looking at kratom gummies online or in a store, and they all claim to be high quality. Premium ingredients, potent extract, laboratory tested, maximum strength. Everyone says their gummies are the best. How do you actually separate quality products from mediocre ones that are just good at marketing? Let’s go through the real indicators that matter. Quality varies dramatically in the kratom gummy market. Learning to spot the difference protects your money and ensures you’re getting what you pay for. Lab Testing Documentation This is the single most important quality indicator. Some products use high-grade kratom extract gummies with proper testing and quality ingredients. Look for a QR code on the package, a batch number you can look up on the company website, or lab reports posted online. The company should make it easy to access test results, not hide them or make you email customer service. What quality lab reports show: – Alkaloid content (mitragynine and 7-hydroxymitragynine levels) – Heavy metals screening (lead, arsenic, mercury, cadmium) – Microbial contamination tests (bacteria, mold, yeast) – Pesticide screening if applicable – Batch-specific results, not generic reports Third-party testing means an independent laboratory tested the product, not the manufacturer’s own lab. Look for recognizable testing facility names on the certificate of analysis. If you can’t find any testing information after checking the package and the company website, that’s a major red flag. Quality manufacturers test their products and proudly share results. Companies that skip testing are cutting corners. Ingredient Quality and Transparency Flip the package over and read the ingredient list. Quality gummies have straightforward, clean ingredient lists. You should see kratom extract or Mitragyna speciosa extract listed prominently. It should be one of the first few ingredients, not buried at the end of a long list. Quality ingredient indicators: – Kratom extract clearly listed and prioritized – Recognizable ingredients you can identify – Natural flavors and colors when possible – Minimal unnecessary additives – No synthetic research chemicals or questionable compounds Red flag ingredients: – Vague terms like ‘proprietary blend’ without details – Long lists of artificial chemicals and preservatives – Kratom listed near the end after many fillers – Ingredients you can’t identify or research – Warning labels about synthetic compounds Some additives are normal and necessary. Gelatin or pectin forms the gummy base. Natural flavors and sweeteners make them palatable. A small amount of preservative extends shelf life. That’s all fine. What you’re watching for is excessive fillers that serve no purpose or questionable compounds that shouldn’t be in a quality product. Extract Quality and Concentration Not all kratom extract is created equal. The concentration and quality of extract determines how well the gummies work. Quality manufacturers specify the extract type. You might see terms like ‘full spectrum extract’ or specific alkaloid percentages. This transparency indicates they’re using proper extract, not just powdered leaf. Check the alkaloid content if it’s listed. High-quality kratom extract gummies typically contain specific amounts of mitragynine and 7-hydroxymitragynine. These numbers should be verifiable through lab testing. Be skeptical of vague claims like ‘maximum strength’ or ‘ultra potent’ without specific numbers backing them up. Anyone can make these claims. Quality manufacturers provide actual data. Physical Appearance and Texture You can learn a lot by actually looking at and handling the gummies. Quality visual indicators: – Consistent color across all gummies in the package – Uniform size and shape – Smooth texture without excessive sugar coating – No visible separation or oil on the surface – Properly sealed, professional packaging Quality concerns to watch for: – Gummies stuck together in clumps – Inconsistent colors or
-
Anthropic Supply Chain Risk Designation Sparks Fierce Backlash from Tech Industry Leaders
WASHINGTON, D.C. – June 9, 2025 – A significant coalition of technology professionals has launched a forceful challenge against the U.S. Department of Defense. They are protesting its unprecedented move to label AI safety pioneer Anthropic as a ‘supply chain risk.’ This designation, typically reserved for foreign adversaries, has ignited a fierce debate about government overreach, corporate ethics, and the future of artificial intelligence development in America. The controversy stems directly from Anthropic’s refusal to grant the Pentagon unrestricted access to its advanced AI systems, citing ethical red lines concerning mass surveillance and autonomous weapons. Anthropic Supply Chain Risk Label Triggers Industry-Wide Alarm Hundreds of employees from leading technology and venture capital firms have signed an open letter. This document urgently calls for the DOD to withdraw its designation. Furthermore, it requests Congressional oversight to examine the appropriateness of applying such extraordinary authorities against a domestic technology company. Signatories hail from prominent organizations including OpenAI, Slack, IBM, Cursor, and Salesforce Ventures. Their collective action highlights deep-seated concerns within the tech ecosystem. The dispute erupted after Anthropic, last week, declined a Pentagon request for unfettered military access to its AI models. The company’s leadership established two non-negotiable ethical boundaries during negotiations. Mass Surveillance Prohibition: Anthropic would not allow its technology to facilitate mass surveillance programs targeting American citizens. Anthropic would not allow its technology to facilitate mass surveillance programs targeting American citizens. Autonomous Weapons Ban: The company refused to power lethal autonomous weapons systems that make targeting and firing decisions without explicit human control. The Department of Defense publicly stated it had no plans to pursue those specific applications. However, officials argued they should not be constrained by the contractual limitations of a private vendor. This fundamental disagreement over control and ethics led to a complete impasse. Government Retaliation and Legal Challenges Escalate Conflict Following Anthropic CEO Dario Amodei’s firm stance, the administration’s response was swift and severe. President Donald Trump directed federal agencies to cease using Anthropic’s technology after a six-month transition period. Pentagon official Hegseth followed through on earlier threats. He announced the intent to formally designate Anthropic a supply chain risk. This action would effectively blacklist the AI lab from any contract or partnership with entities conducting business with the U.S. military. Importantly, a social media post does not enact this designation. The government must complete a formal risk assessment and notify Congress before enforcement. Anthropic has vowed to challenge any such designation in court, calling it ‘legally unsound.’ Many industry observers interpret the administration’s aggressive posture as clear retaliation for the company’s ethical stand. Expert Analysis: A Dangerous Precedent for Tech Governance The tech workers’ open letter articulates a widespread fear. It states, ‘When two parties cannot agree on terms, the normal course is to part ways and work with a competitor. This situation sets a dangerous precedent. Punishing an American company for declining to accept changes to a contract sends a clear message to every technology company in America: accept whatever terms the government demands, or face retaliation.’ This sentiment resonates across Silicon Valley. It raises critical questions about the balance of power between innovative private enterprises and government procurement needs. The use of a ‘supply chain risk’ label, a tool designed for national security threats from abroad, against a domestic firm is viewed as a significant escalation. It potentially weaponizes procurement policy to compel compliance. Key Events in the Anthropic-DOD Dispute Timeline Date Event Key Stakeholder Early May 2025 Contract negotiations begin between Anthropic and DOD. Anthropic, Pentagon June 2, 2025 Anthropic refuses unrestricted access, cites ethical red lines. Dario Amodei (Anthropic CEO) June 6,
-
A Modest Proposal Concerning AI Hallucinations
We added a new site to our blogroll recently – ‘AI Hallucination Cases,’ which describes itself as: This database tracks legal decisions in cases where generative AI produced hallucinated content – typically fake citations, but also other types of AI-generated arguments. . . . While seeking to be exhaustive (972 cases identified so far), it is a work in progress and will expand as new examples emerge. . . . Of the (as of this writing) 972 judicial decisions the site identifies, over two-thirds (676) are from the United States. Not surprisingly, more than half of the cases involve pro se litigants, but in almost 400 (391) of the listed decisions the perpetrators of AI hallucinations were actual lawyers, who, by definition, are supposed to know better. Unfortunately, the problem does not seem to be getting any better. The number of judicial opinions involving actual lawyers (non-pro se) accused of passing off AI hallucinations in filed documents for the incomplete month of February 2026 (it’s 2/23/26 as we write this post) is thirty-three (31 of which were in the USA), which is significantly more than a decision a day. For January 2026, the number is thirty-six (25 of which were in the USA). For December 2025, the number was fifty-one (36 of which were in the USA). We didn’t do any detailed counts before then, but anyone who wants to can go to the site and verify our numbers. A lawyer’s use of AI hallucinated anything in a filed document is unethical. It’s a fraud on the court and opposing parties. It’s lack of candor with the court. It’s unprofessional since at minimum the presence of such hallucinations demonstrates incompetent use of technology. See ABA Model Rules of Prof. Conduct, Rule 1.1. In federal court, it’s an open-and-shut violation of Fed. R. Civ. P. 11 for not reading what was cited in signed, filed papers. The Fifth Circuit, in a recent published opinion, held that ‘submitting a brief riddled with fabricated quotations’ is conduct ‘unbecoming a member of the bar’ that violates F.R.A.P. 46(c). Fletcher v. Experian Information Solutions, Inc., ___ F.4th ___, 2026 WL 456842, at *2, 6 (5th Cir. Feb. 18, 2026) (citing, inter alia, the same website we mentioned above). Moreover, it’s stupid as hell. There’s nothing easier for the other side to identify than legal citations and quotations that don’t in fact exist. Can any lawyer reasonably believe that the other side isn’t going to review the cases that s/he cites? There are even AI programs available to detect AI hallucinations, including in legal filings. Once hallucinations are detected, the party responsible is essentially caught red-handed with virtually no defense. Then the perpetrator ends up like the attorney in Fletcher, or in this recent prescription medical product liability-adjacent decision: Plaintiff has submitted dozens of inaccurate factual and legal citations across at least five different filings. Regardless of any use of generative artificial intelligence, erroneous citations suggest Plaintiff’s counsel submitted these filings without ‘conduct[ing] a reasonable inquiry into the facts and the law’ as required by Rule 11(b). When confronted with similar situations, courts have ordered the filing attorneys to show cause why sanctions or discipline should not issue. The Court finds such an order is appropriate here. Ledoux v. Outliers, Inc., 2026 WL 291023, at *3 (W.D. Wash. Feb. 4, 2026) (citations and quotation marks omitted). Something needs to be done about this. We had hoped that embarrassment stemming from the broad public disclosure of the initial instances of attorneys found responsible for AI hallucinations would have been enough of a deterrent. But our hope in
-
Esha Gupta says ‘It’s not a pleasant situation’ as she remains stuck in UAE
As tensions continue to escalate in the Middle East after the United States and Israel attacked Iran, the airspace was one of the first closures announced.
Due to the tensions, several flights were cancelled and suspended, leaving thousands of passengers stranded. Among several Indian celebrities, actress Esha Gupta is also stuck in Abu Dhabi. Iran targeted several key locations in the UAE, including near locations in Dubai Airport and Burj Al Arab, in retaliatory missile attacks.
On Sunday, Esha took to her Instagram to share her thoughts as she is in a volatile situation. However, the actress hailed the UAE government for caring for people stranded at the airport.
Also read: From Ajith Kumar to Esha Gupta: Indian celebrities stranded in Dubai, Saudi Arabia amid US–Israel attack on Iran
The actress, who is in Abu Dhabi, said that the situation is under control in the city. ‘Incredible job by @uaegov for taking care of every stranded person at the airport, from giving for food to airport transfers to hotel accommodation. How well the situation in #abudhabi is managed shows how powerful the country is as how calmly they are protecting everyone,’ Esha wrote.
The actor further shared, ‘Special mention to @modgovae Again everyone, I’m sorry it’s not a pleasant situation, apology for. NOT taking calls or msgs, just wish to be able to fly back home soon.’
Esha has been stranded in Dubai and has been updating her fans and followers through Instagram.
Also read: Actor Awards: Sinners dominates, Catherine O’Hara honoured with Best Actress
On Sunday, the actress reassured fans, saying,” ‘To everyone checking in and messaging, I’m sorry for not replying. We are ok, we are safe! Times are scary, very tough. God is there to protect us. We trust the @modgovae is doing the best in protecting and interception.’
She added, ‘Praying for everyone effected. all those stranded and safety for all above all. Hope to be home soon.’
Apart from Esha, Tamil cinema actor Ajith Kumar and actor Sonal Chauhan are stranded in the UAE. Meanwhile, Chauhan shared a note on Instagram and reached out directly to Prime Minister Narendra Modi, requesting him to help in the safe return to India. -
Ankr Health CEO Ray Rao, MD to Participate as Panelist on Agentic AI Workflows at MedTech Rodeo 2026
Panel will explore how agentic AI workflows are transforming medical front-office operations and helping specialty practices expand patient access
SAN FRANCISO, CA, UNITED STATES, February 27, 2026 / EINPresswire.com / — Ankr Health, a Y Combinator and MedTech Innovator–backed company that has pioneered AI employee solutions for medical practices, today announced that its Chief Executive Officer, Ray Rao, MD, will participate as a panelist at MedTech Rodeo 2026, taking place March 3-4, 2026 in Houston, TX.
Dr. Rao will participate in the panel discussion, ‘Agentic Workflow: MedTech’s Next Productivity Breakthrough’ scheduled for March 4, 2026, from 1:00 PM to 2:00 PM CST. Other panelists include Tony Mango of Orlando Health, Darcy Bachert and Chris Kennedy of Prolucid, Robert Hamilton of NeuraSignal, and Nader Fathi of Enlil, Inc.
‘Healthcare access is increasingly constrained not by clinical capacity, but by front-office operational bottlenecks,’ said Ray Rao, MD, CEO of Ankr Health. ‘AI employees represent a fundamental shift–from software that merely assists staff to a package of capabilities that not only executes complex operational tasks in clinics, but also communicate with patients, doctors and staff on phone, emails, Teams, and EHR inboxes.
Across multiple specialties and in clinics nationwide, Ankr’s AI employees have demonstrated ability to:
– Independently schedule appointments in multiple EHR systems,
– Write phone encounter and clinic visit notes,
– Answer 1000+ calls a day without breaks and with exceptional patient satisfaction scores
‘Ankr customers have generated $25,000+ in net new per-physician revenue while improving margins and patient satisfaction. This is the story that we are excited to share with the distinguished attendees at MedTech Rodeo.’
Registration Information
To attend MedTech Rodeo 2026 and the Agentic Workflow panel, register at:
https://www.houstonmedtech.org/events/rodeo1/#e3e4c3c3-b1b2-43d6-8e24-785f4f29dd0b
About Ankr Health
Ankr Health is a venture-backed healthcare technology company building one intelligent platform for medical front-office operations. Its flagship platform, VCX ®, augments medical workforce across various roles (medical assistants, scheduler, triage nurse, receptionist, and scribe). By coordinating decisions and workflows end-to-end, rather than deploying isolated point solutions, Ankr helps specialty practices expand patient access, reduce administrative strain, and operate sustainably amid rising demand and workforce constraints. Ankr Health is backed by Y Combinator and MedTech Innovator.
To learn more about Ankr Health and its VCX platform, visit www.ankrhealth.com and follow the company on LinkedIn for updates.
About MedTech Rodeo 2026
MedTech Rodeo is a leading industry event convening healthcare innovators, investors, and executives to discuss emerging technologies, commercialization strategies, and the future of medical technology. The 2026 event will be held March 3-4, 2026, at Armadillo Palace in Houston, Texas.
Media Contact:
Madelyn De Los Santos
Putnam Insights
madelyn@putnaminsights.com
Legal Disclaimer: -
Barisan Nasional plans progressive rebrand to stay relevant
BN secretary-general Datuk Seri Dr Zambry Abd Kadir – BERNAMA filepic
KUALA LUMPUR: Barisan Nasional (BN) has concluded that a rebranding exercise is necessary for the coalition to emerge as a more progressive and inclusive entity aligned with current public aspirations.
BN secretary-general Datuk Seri Dr Zambry Abd Kadir stated that the rebranding must be founded on balanced, moderate, and consensus-based politics without abandoning the coalition’s foundational struggle and core values.
This matter was a major focus during a recent BN leadership retreat designed to strengthen unity and plan strategic forward measures for all component parties.
Zambry explained that the leadership collectively stressed commitments to ensure unity and internal strength to keep BN relevant as the best choice in Malaysia’s dynamic political landscape.
He added that the coalition agreed political consolidation must be pursued in an organised and realistic manner according to current developments.
The retreat gathered leaders from UMNO, MCA, MIC, Parti Bersatu Rakyat Sabah (PBRS), Parti Progresif Penduduk (PPP), and the Friends of BN president.
Zambry said the full attendance reflected a strong spirit of togetherness and a shared determination to strengthen the coalition’s position as an important foundation in national politics.
The coalition also agreed to begin immediate preparations for all possibilities, including upcoming state elections in Melaka and Johor as well as the next general election.
Discussions highlighted a joint concern for maintaining national peace and stability, with BN’s stance being that sensitive racial and religious issues must be tackled through consensus, moderation, and political wisdom.
Zambry reiterated that BN’s leadership within the government will continue to execute its duties responsibly and play a constructive role in strengthening the Unity Government under Prime Minister Datuk Seri Anwar Ibrahim. -
Radcom Ltd. (NASDAQ:RDCM) Sees Significant Increase in Short Interest
Radcom Ltd. (NASDAQ:RDCM – Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 105,612 shares, a growth of 49.5% from the January 29th total of 70,658 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average daily volume of 127,368 shares, the short-interest ratio is currently 0.8 days. Based on an average daily volume of 127,368 shares, the short-interest ratio is currently 0.8 days. Currently, 2.1% of the company’s shares are sold short. Get Radcom alerts: Sign Up Analyst Upgrades and Downgrades RDCM has been the topic of several recent analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Radcom in a report on Monday, December 22nd. Needham & Company LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Radcom in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $18.00. View Our Latest Research Report on Radcom Institutional Inflows and Outflows A number of large investors have recently made changes to their positions in RDCM. Corton Capital Inc. acquired a new stake in shares of Radcom in the 2nd quarter worth about $210,000. Acadian Asset Management LLC grew its stake in shares of Radcom by 13.3% in the 2nd quarter. Acadian Asset Management LLC now owns 326,110 shares of the technology company’s stock worth $4,406,000 after acquiring an additional 38,284 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Radcom by 20.5% in the 2nd quarter. Marshall Wace LLP now owns 110,127 shares of the technology company’s stock worth $1,497,000 after acquiring an additional 18,708 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Radcom in the second quarter valued at about $165,000. Finally, Raymond James Financial Inc. bought a new position in shares of Radcom during the second quarter valued at about $34,000. 48.32% of the stock is owned by institutional investors. Radcom Trading Down 1.7% RDCM opened at $11.39 on Friday. The company has a fifty day moving average price of $12.51 and a two-hundred day moving average price of $13.17. Radcom has a 1-year low of $9.88 and a 1-year high of $15.15. The company has a market cap of $186.91 million, a P/E ratio of 15.82 and a beta of 0.56. Radcom (NASDAQ:RDCM – Get Free Report) last posted its quarterly earnings results on Wednesday, February 11th. The technology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Radcom had a return on equity of 11.53% and a net margin of 16.77%.The business had revenue of $18.86 million for the quarter, compared to the consensus estimate of $18.46 million. On average, research analysts forecast that Radcom will post 0.54 EPS for the current fiscal year. About Radcom Radcom Ltd. NASDAQ: RDCM is a provider of cloud-based service assurance and analytics solutions designed to help communications service providers monitor and optimize the performance of their networks. Its flagship product, RADCOM ACE, delivers real-time visibility into service quality, subscriber experience and network resource utilization across traditional and virtualized architectures. By combining packet-level data collection with advanced analytics and machine-learning algorithms, Radcom enables carriers to detect, troubleshoot and resolve network and service issues before they impact end users.